Author Archives: admin


Stem Cell Clinic > Articles by: admin

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

See the rest here:
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Radiance Announces First Patient Dosing in Phase 1 Clinical Trial of its Next Generation ROR-1 Targeted ADC for Hematologic and Solid Malignancies

By Global News Feed

BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today announced that the first patient in China has been dosed in the Phase 1 clinical trial of RB-164™ (SYS6005), a next-generation antibody-drug-conjugate (ADC) targeting ROR-1.

Continue reading here:
Radiance Announces First Patient Dosing in Phase 1 Clinical Trial of its Next Generation ROR-1 Targeted ADC for Hematologic and Solid Malignancies

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

By Global News Feed

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study2.

Continue reading here:
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

Theratechnologies Provides Update on Sale Process

By Global News Feed

MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the “Board”) has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with this determination, the Board has authorized the special committee, consisting of independent and disinterested directors (the “Special Committee”), to oversee the process and make a recommendation to the full Board. To support this process, in addition to Barclays as financial advisor and Fasken as legal advisor, the Special Committee has also engaged Raymond James as independent financial advisor and Norton Rose Fulbright as independent legal advisor.

See the original post here:
Theratechnologies Provides Update on Sale Process

Raw Garden Launches Blockbuster Deals for 4/20 Across California

By Global News Feed

SANTA BARBARA, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Raw Garden, the leader in clean and green California cannabis, is celebrating 4/20 with a series of exciting events and promotions across the state. Known for commitment to purity and sustainability, Raw Garden offers 100% pure cannabis oil and terpenes, free from junk like additives and pesticides.?

Here is the original post:
Raw Garden Launches Blockbuster Deals for 4/20 Across California

Leqembi®? (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

By Global News Feed

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ?4 (ApoE ?4*) non-carriers or heterozygotes with confirmed amyloid pathology

Read the original:
Leqembi®? (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

→←